Cereno Scientific AB Announces New Board Nomination and Investor Day Presentation

Cereno Scientific AB, a Swedish biotechnology company listed on the Frankfurt Stock Exchange, has recently made significant announcements regarding its board composition and upcoming investor presentations. The company, known for developing groundbreaking treatments for rare cardiovascular and lung diseases, is preparing for key events in the coming months.

Board Nomination Ahead of Annual General Meeting

On May 7, 2025, Cereno Scientific’s Nomination Committee proposed a new board with a focus on mergers and acquisitions (M&A). This proposal is set to be discussed at the company’s Annual General Meeting (AGM), initially scheduled for June 10, 2025. However, a correction was issued later that day, clarifying that the AGM is actually set for May 10, 2025. This strategic move aims to strengthen the company’s position in the market by enhancing its M&A capabilities.

Investor Day Presentation

In addition to the board changes, Cereno Scientific is set to present at the ABGSC Investor Days on May 13-14, 2025, in Stockholm. The event will feature Sten R. Sörensen, the company’s CEO, who will present on Tuesday, May 13, at 16:00 in “Track 1.” The presentations will be live-streamed and made available on the ABGSC and Cereno’s websites following the event. This presentation is an opportunity for investors to gain insights into the company’s innovative treatments and future plans.

Company Overview

Cereno Scientific AB, with a market capitalization of 2,263,290,634 SEK, is listed on the Swedish Stock Exchange and trades in SEK. As of May 4, 2025, the company’s close price was 8.13 SEK, with a 52-week high of 9.5 SEK on September 29, 2024, and a low of 3.49 SEK on May 15, 2024. The company’s focus on developing life-enhancing treatments positions it as a leader in the biotechnology sector.

For more information about the ABGSC Investor Days or to contact the company, interested parties can reach out to Tove Bergenholt, Head of IR & Communications, or Sten R. Sörensen, CEO, via the provided contact details.